The Oxford, Conn.-based BrachySciences, a division of Biocompatibles International, has signed an agreement with IsoRay to distribute its Proxcelan Cesium-131 brachytherapy seeds.

"Management believes this distribution agreement will enable us to increase the sales of Cesium-131 within the prostate cancer therapy market. This supports our ongoing strategy of driving sales by adding an additional outside distribution channel to augment our current sales staff," said Dwight Babcock, IsoRay's chairman and CEO.

The Richland, Wash.-based IsoRay said it remains committed to bringing products and services to the brachytherapy market.